Dana Farber Cancer Institution is a clinical research site located in Boston, Massachusetts, United States 02215.
Crixeo Health Trust Score: 65/100 (FAIR). This profile has not yet been claimed by the site owner.
Dana Farber Cancer Institution has participated in 2 clinical trials.
Therapeutic areas: Cholangiocarcinoma, Urothelial Cancer, Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors.
Sponsors: Taiho Oncology, Inc., Syndax Pharmaceuticals.
Trust Score: 65/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.
Dana Farber Cancer Institution has a Crixeo Trust Score of 65/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
Dana Farber Cancer Institution has 2 clinical trials on record. Their work covers Cholangiocarcinoma, Urothelial Cancer, Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors.
Dana Farber Cancer Institution has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.